Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling

YANDONG LU1*, FANGGUO LI1*, TAO XU2 and JIE SUN1

1Department of Orthopaedic Traumatology, Tianjin Hospital, Hexi, Tianjin 300211; 2Department of Orthopaedics, Jixian People's Hospital, Jixian, Tianjin 301900, P.R. China

Received November 9, 2015; Accepted January 16, 2017

DOI: 10.3892/ijmm.2017.2895

Abstract. The development of multidrug resistance (MDR) remains a major limitation to successful chemotherapy in osteosarcoma. Preventing the introduction of MDR has been a research hotspot in clinical and investigational oncology. The aim of this study was to evaluate the preventive effects of tetrandrine (TET) against MDR in osteosarcoma. For this purpose, U-2OS human osteosarcoma cells were treated with paclitaxel alone or a combination of paclitaxel with TET. The cells treated with paclitaxel alone eventually acquired MDR along with the overexpression of and highly activated P-glycoprotein (Pgp), while the cells treated with the paclitaxel-TET combination were sensitive to chemotherapeutic drugs and expressed decreased levels of Pgp and less Pgp activity. The promoter activities of MDR gene 1 (MDR1) and nuclear factor (NF)-κB, and the expression levels of NF-κB and p-IκB-α were all enhanced in the cells cultured with paclitaxel alone. NF-κB DNA-binding activity and the binding ability of NF-κB to the MDR1 promoter were also enhanced in the cells cultured with paclitaxel alone compared to the control cells. However, the expression and activity of NF-κB were significantly decreased in the paclitaxel-TET combination-treated group as compared with the cells treated with paclitaxel alone. On the whole, our findings suggest that TET prevents paclitaxel-induced MDR by inhibiting Pgp overexpression through a mechanism that may involve the inhibition of NF-κB signaling in osteosarcoma.

Introduction

Osteosarcoma, one of the malignant bone tumors, predominantly occurs in children and adolescents (1-3). Currently, the treatment for osteosarcoma mainly includes surgery and combination chemotherapy (4,5). Multidrug resistance (MDR) is a formidable obstacle of chemotherapy in the treatment of osteosarcoma (6-8). Tumor cells can develop resistance to a wide variety of anticancer drugs, whose structure and function are usually unrelated, thus limiting the curative effects of chemotherapeutic drugs (9,10). Therefore, the understanding of the pathological mechanisms of MDR is of great importance for developing effective therapies for osteosarcoma.

It has been reported that there are several mechanisms responsible for osteosarcoma becoming resistant to chemotherapeutic agents (6). One mechanism is the overexpression of ATP-binding cassette (ABC) transporters in cells which develop MDR, which causes reduced drug uptake and enhanced drug efflux (11-13). P-glycoprotein (Pgp), one of the most important ABC transporters, is encoded by MDR gene 1 (MDR1) (14). Pgp overexpression has been detected in multiple osteosarcoma cell lines with MDR and residual tumor cells in post-chemotherapy patients (14-17). Numerous drugs in osteosarcoma chemotherapy are substrates of Pgp, including doxorubicin, paclitaxel, vinblastine, vincristine and etoposide (18).

Pgp-mediated resistance to drugs can be reversed by inhibiting MDR1 drug pump function or by preventing MDR1 expression (11). A number of studies have been carried out on Pgp-mediated MDR. Various Pgp inhibitors have been developed, such as verapamil, PSC833, VX-710 and XR9576 (19), and curcumin has also been shown to inhibit Pgp (20). Over the past decade, preventing the initiation of MDR following chemotherapy has gained much attention (21-24). A variety of drugs, including verapamil, CsA, P85 and LGD1069 have been found to be preventers, averting the emergence of MDR (21,22,24,25). Although clinical trials examining these preventers have been initiated, notable therapeutic results have not been acquired in these trials (26-29). Thus, exploring more potent and selective MDR preventers is of utmost importance.

Tetrandrine (TET), a bis-benzylisoquinoline alkaloid compound, was isolated from the root of Stephania tetrandra. TET is utilized as an anti-rheumatic, anti-inflammatory and anti-hypertensive agent with low toxicity in traditional Chinese medicine (30). Moreover, TET exhibits antitumor activity in both tumor cells and animal models (31-34). It has been reported that TET treatment can cause the notable
downregulation of Pgp expression, which significantly reverses drug resistance in leukemia cells (35). Furthermore, TET has the ability to stimulate Pgp ATPase activity, thereby reversing Pgp-mediated MDR in cancer cells (36). Additionally, studies have demonstrated that TET can inhibit the development of MDR by preventing Pgp overexpression in the leukemia cell line, K562 (37). However, whether TET has the ability to prevent the enmgergence of MDR in osteosarcoma has yet to be determined.

In the present study, we evaluated the effects of TET on the prevention of MDR in the osteosarcoma cell line, U-2OS, and investigated the underlying mechanisms.

Materials and methods

Drugs and cell line. TET was supplied from Sigma-Aldrich (St. Louis, MO, USA). Paclitaxel, doxorubicin, vincristine, gemcitabine and methotrexate were supplied from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Docetaxel and cisplatin were supplied from Sigma-Aldrich. PM-00104 was purchased by PharmaMar (Madrid, Spain). The human osteosarcoma cell line, U-2OS, was supplied from the American Type Culture Collection (ATCC, Manassas, VA, USA), cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (both from Invitrogen Life Technologies, Carlsbad, CA, USA) in a humidified atmosphere of 5% CO₂ at 37°C.

Development of resistant osteosarcoma cell line. In our study, the establishment of a resistant osteosarcoma cell line followed similar previously described protocols (21,23,38). A paclitaxel-resistant cell line was established from the parental cell line, U-2OS. The culture medium was supplemented with 0.0001 µM paclitaxel alone, 1 µM TET alone or a combination of 1 µM TET and 0.0001 µM paclitaxel. When the cells reached 90% confluence, they were harvested and then resuspended, and cultured in medium with an increased paclitaxel concentration. The cells were then treated with increasing concentrations of paclitaxel over a period of 6 months. Cell sublines at different selection points were stored in liquid nitrogen for further analyses.

Cell groups. The groups were divided into the control cells (U-2OS/control), cells treated with TET alone (U-2OS/tetrandrine), 6 resistant U-2OS cell lines that developed resistance with final paclitaxel concentrations of 0.003, 0.006, 0.03, 0.06, 0.1, 0.2 µM paclitaxel, respectively (paclitaxel₀₀₀₃, paclitaxel₀₀₀₆, paclitaxel₀₀₃, paclitaxel₀₀₆, paclitaxel₀₆₀, paclitaxel₁₀ and paclitaxel₂₀) and 2 non-resistant U-2OS cell lines that were exposed to a combination of 0.003 or 0.006 µM paclitaxel with 1 µM TET (paclitaxel₀₀₀₃/tetrandrine and paclitaxel₀₀₀₆/tetrandrine).

Cytotoxicity assay. The cytotoxicity of chemotherapeutic agents in the different cell sublines was evaluated by MTT assay. In brief, the cells were seeded in 96-well plates and treated with various concentrations (0.0001, 0.001, 0.01, 0.1, 1, 10 and 100 µM) of chemotherapeutic agents for 5 days, followed by the addition of 20 µl of MTT (Sigma-Aldrich) to each well for 4 h. The crystals were dissolved in 100 µl DMSO. The absorbance at 490 nm was measured using a Bio-Rad microplate reader (Bio-Rad, Hercules, CA, USA). Experiments were performed in triplicate. The IC₅₀ value was analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).

Reverse transcription-quantitative PCR (RT-qPCR). The mRNA expression level of MDR1 was determined by RT-qPCR. TRIzol reagent (Invitrogen) was used to extract total RNA according to the manufacturer’s instructions. The primeScript RT reagent kit (Takara, Dalian, China) was used to reverse transcribe the RNA into cDNA, then stored at -20°C. cDNA was amplified using a SYBR Premix Ex Taq kit (Takara) and Mx3000P instrument (Agilent Technologies, Inc., Santa Clara, CA, USA). PCR programs were carried out as follows: 95°C for 5 min, followed by 30 cycles of 95°C for 30 sec, 56°C for 30 sec, 72°C for 30 sec, and a final extension for 5 min at 72°C. PCR products were analyzed according to the 2⁻ΔΔCt method with β-actin as the standard gene.

Western blot analysis. The protein expression levels were determined by western blot analysis. Each group of cells was collected and washed with phosphate-buffered saline (PBS). The total protein extraction kit (KeyGen Biotech Co., Ltd., Nanjing, China) was used to extract the total protein according to the manufacturer’s instructions. The BCA protein assay kit (KeyGen Biotech Co., Ltd.) was used to determine the protein concentrations. Briefly, an aliquot of total protein was run on SDS-PAGE and transferred onto nitrocellulose membranes (Millipore, Billerica, MA, USA), which were blocked with 5% BSA-PBS at room temperature for 1 h, and subsequently incubated overnight with primary antibodies against Pgp (Cat. no. HPA002199, Sigma-Aldrich), p-IkB-α (Cat. no. 28598, Cell Signaling Technology, Danvers, MA, USA) or GAPDH (Cat. no. sc-20357, Santa Cruz Biotechnology) at 4°C, respectively. To determine the NF-κB expression level, total nuclear protein was prepared using a commercial kit (KeyGen Biotech Co., Ltd.) according to the manufacturer’s instructions. Following incubation with primary antibodies, the membranes were rinsed 3 times with PBS and anti-rabbit IgG (Cat. no. 4414, Cell Signaling Technology) and anti-mouse IgG (Cat. no. 4408, Cell Signaling Technology) were then added at a dilution of 1:10,000 followed by incubation at room temperature for 1 h. Finally, the membranes were detected and quantified using the LI-COR Odyssey infrared imaging system and software (LI-COR Biosciences, Lincoln, NE, USA).

Rh123 accumulation assay. The different cell groups were incubated at a concentration of 0.5 mg/ml fluorescent dye, Rh123 (Sigma-Aldrich) for 2 h. The cells were harvested and washed twice with PBS, then suspended and kept in the dark. The intracellular Rh123 was determined using a flow cytometer (Becton Dickinson, San Diego, CA, USA). The data were analyzed using FlowJo 7.6.2 software (Tree Star Inc., Ashland, OR, USA).

Dual-luciferase reporter assay. The promoter activity was determined by a dual-luciferase reporter assay. Plasmid preparation was performed as previously described (39). The cells were plated in 24-well plates overnight. Using Lipofectamine 2000 according to the instructions provided by the manufacturer (Invitrogen), the cells were co-transfected transiently with an hMDR1-Luc or NF-κB-Luc construct and...
pRL-SV plasmid (Renilla luciferase expression for normalization) (Promega, Madison, WI, USA). Luciferase activity in the cell lysates was measured using a dual-luciferase reporter assay kit (Promega).

NF-κB DNA-binding activity assay. The DNA-binding activity was determined by electrophoretic mobility shift assay (EMSA), as previously described (37). The concentration of the nuclear protein of cells from different cell sublines was quantified by BCA assay. Equal amounts of nuclear protein (2 μl) were mixed with P-labeled NF-κB binding probe (1 μl), nuclease-free water (5 μl) and EMSA/gel-shift binding buffer (5X; 2 μl). The mixture was incubated at room temperature for 20 min. The samples were separated by non-denaturing PAGE. The gels were dried and kept in an exposure cassette for 72 h at -70°C for autoradiography.

The binding ability of NF-κB to the MDR1 gene promoter. The binding ability was determined by chromatin immunoprecipitation (ChIP) as described in a previous study (37). A commercially available ChIP assay kit (Upstate Biotechnology, Inc., Lake Placid, NY, USA) was used according to the instructions provided by the manufacturer. Briefly, 7×10⁶ cells in 4 different groups (U-2OS/control, U-2OS/tetrandrine, paclitaxel₁₀₀₀ and paclitaxel₁₀₀₀/tetrandrine) were used. The chromatin fraction was immunoprecipitated with an anti-NF-κB p65 antibody (Cat. no. 06-418, Upstate Biotechnology, Inc.) overnight at 4°C and finally examined by PCR.

Statistical analysis. Statistical analysis was carried out using GraphPad Prism 5 software (GraphPad Software, Inc.). The data in our study are presented as the means ± SD. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

Tetrandrine prevents the emergence of paclitaxel resistance in the osteosarcoma cell line, U-2OS. The U-2OS cells were treated with increasing concentrations of paclitaxel alone or a combination of paclitaxel with 1 μM TET. After 6 months of drug treatment, the cells treated with paclitaxel alone exhibited stable growth in the culture medium with 0.2 μM paclitaxel. By contrast, the cells treated with the paclitaxel-TET combination were not able to grow when treated with paclitaxel at concentrations >0.006 μM in the culture medium (Fig. 1A). The IC₅₀ value of paclitaxel was then evaluated to further confirm the effects of TET on paclitaxel resistance. As shown in Fig. 1B, the IC₅₀ value of paclitaxel in the cells treated with paclitaxel alone increased as the concentration of paclitaxel increased. In addition, the IC₅₀ value of the U-2OS cells treated with ≥0.03 μM paclitaxel alone was significantly increased compared with the control cells. An enhancement of 64-fold in the IC₅₀ value of paclitaxel was observed in the cells treated with 0.2 μM paclitaxel alone (paclitaxel₁₀₀₀) compared with the control cells. However, the cells treated with the 0.006 μM paclitaxel-TET combination (paclitaxel₁₀₀₀/TET) exhibited no obvious increase in the IC₅₀ value of paclitaxel compared with the control cells. Notably, the IC₅₀ value of paclitaxel in the paclitaxel₁₀₀₀ cells was 53.3-fold higher than that of the paclitaxel₁₀₀₀/TET cells, demonstrating that TET inhibited the initiation of paclitaxel resistance in the osteosarcoma cell line, U-2OS. There was no change in the IC₅₀ value of paclitaxel in the cells treated with 1 μM TET alone (Fig. 1B).

Tetrandrine inhibits the development of MDR in cells treated with paclitaxel and different chemotherapeutic agents. As shown above, TET inhibited the development of paclitaxel resistance. Thus, we further investigated whether TET inhibits resistance to other chemotherapeutic drugs. Compared with the control cells, the IC₅₀ value of doxorubicin, docetaxel and vincristine increased 30-, 16.7- and 8-fold in the paclitaxel₁₀₀₀ cells, respectively. By contrast, the paclitaxel₁₀₀₀/TET cells remained sensitive to these 3 agents and no significant differences in the IC₅₀ values were observed (Fig. 2B, C and D). Apart from doxorubicin, docetaxel and vincristine, the IC₅₀ values of other Pgp substrate drugs, such as PM-00104 and gemcitabine, were also significantly increased in the paclitaxel₁₀₀₀ cells. As expected, the paclitaxel₁₀₀₀/TET cells remained sensitive to PM-00104 and gemcitabine (Fig. 2E and F). Thus, our data indicate that the cells treated with paclitaxel alone naturally developed MDR, whereas the cells treated with the paclitaxel-TET combination did not acquire MDR. Taken together, these results demonstrate that TET was able to inhibit the initiation of MDR in U-2OS cells during continued paclitaxel treatment. Furthermore, the IC₅₀ values of cisplatin and methotrexate (Fig. 2G and H), which are not Pgp substrates, exhibited no significant differences between the paclitaxel₁₀₀₀/TET and paclitaxel₁₀₀₀ cells, suggesting that TET may specifically suppress the development of Pgp-mediated MDR during paclitaxel treatment.

Tetrandrine prevents the development of MDR by inhibiting MDR1 and Pgp. The expression levels of MDR1 and Pgp were examined to investigate the underlying mechanisms responsible for the inhibitory effects of TET on the development of MDR. The results of RT-qPCR revealed that as paclitaxel treatment continued, an obvious stepwise increase in MDR1 expression was observed in the cells treated with paclitaxel alone. However, there was a marked reduction in MDR1 expression in the paclitaxel₁₀₀₀/TET cells compared to the paclitaxel₁₀₀₀ cells, which indicated that TET prevented MDR1 overexpression during paclitaxel treatment (Fig. 3A and C). The results of western blot analysis revealed that the Pgp expression levels in the cells treated with ≥0.03 μM paclitaxel alone were significantly increased compared with those of the control cells. Additionally, the increased Pgp expression levels exhibited a strong correlation with the increased paclitaxel concentration. However, Pgp overexpression was not detected in the cells treated with the paclitaxel-TET combination (Fig. 3B and D), which suggested that TET prevented the initiation of MDR in osteosarcoma by suppressing Pgp overexpression. These results indicated that culture of the cells with paclitaxel alone induced MDR1 and Pgp overexpression, which were responsible for the development of MDR. No significant differences in MDR1 and Pgp expression levels were detected in the cells cultured with the paclitaxel-TET combination compared to the control group. Taken together, our data indicated that TET prevented the emergence of MDR in the U-2OS cells by preventing the overexpression of MDR1 and Pgp during paclitaxel treatment.
Treatment of the cells with 1 μM TET alone had no effect on the expression of MDR1 and Pgp.

**TET decreases Pgp activity, characterized by maintaining the intracellular retention of Rh123.** The intracellular accumulation level of Rh123 was examined by flow cytometry to identify the functional activity of Pgp. Rh123 is a substrate of Pgp with yellow-green fluorophores. The lower retention of fluorescence intensity inside cells indicates a higher activity of the Pgp pump (40). As shown in Fig. 4, a considerable difference was
observed between the cells cultured with the paclitaxel-TET combination and those cultured with paclitaxel alone. The fluorescence intensity of Rh123 in the paclitaxel 0.2 group was lower compared with that in the control cells and increased significantly in the paclitaxel 0.006/TET cells as compared with the paclitaxel 0.2 cells. In addition, treatment with TET alone had no obvious effect on Pgp activity. The accumulation activity of Pgp was related to the expression level of Pgp, strongly indicating that TET maintained the intracellular retention of a Pgp substrate by suppressing the overexpression of Pgp. TET inhibits the overexpression of Pgp by inhibiting the NF-κB signaling pathway. A recent study found a mutation of a NF-κB binding site located to the MDR1 promoter (41). Furthermore, the overexpression of Pgp is regulated by the NF-κB signaling pathway, and thus requires a NF-κB binding site in the MDR1 promoter (42). To better understand the underlying mechanisms responsible for the inhibitory effect of TET on MDR, the promoter activities of MDR1 and NF-κB were detected by dual-luciferase reporter assay. Both MDR1 and NF-κB transcriptional activities were significantly increased in the paclitaxel 0.2 cells compared with the control cells. However, in the cells treated with paclitaxel 0.006/TET, these transcriptional activities were significantly inhibited and were similar to those of the control cells (Fig. 5A and B), implying that the inhibition of MDR1 activity, at least in part, may be associated with the downregulation of NF-κB activity. As a transcription factor, NF-κB translocates to the nucleus to exhibit transcriptional activity. Therefore, we detected the expression of NF-κB in the nucleus by western blot analysis (Fig. 5C and D). Additionally, the phosphorylation of IκB-α is required for the activation of NF-κB. Thus, we also assessed the p-IκB-α protein levels (Fig. 5C and E). The level of nucleic NF-κB was markedly upregulated in the paclitaxel 0.2 cells compared to the control cells. In the paclitaxel 0.006/TET cells, however, NF-κB protein expression was decreased compared with the paclitaxel 0.2 cells. Similar to NF-κB, the expression of p-IκB-α in the paclitaxel 0.2 cells was 6.3-fold higher compared to that of the control cells; however, there was no difference between the paclitaxel 0.006/TET and the control cells.

To further investigate the inhibition of NF-κB transcriptional activity by TET, NF-κB DNA-binding activity was assessed by EMSA. This assay demonstrated that the NF-κB DNA-binding activity in the paclitaxel 0.2 cells was notably enhanced as compared with that of the control cells, but was reduced in the paclitaxel 0.006/TET cells, suggesting that TET inhibited NF-κB DNA-binding activity, which may prevent Pgp overexpression in U-2OS cells (Fig. 5F). To verify that the inhibitory effect of TET on Pgp is regulated by NF-κB signaling, a ChIP assay was performed. As shown in Fig. 5G, the amplified PCR product was evident, implying that NF-κB was bound to the MDR1 promoter. In the paclitaxel 0.2 cells, the PCR product was markedly increased, which demonstrated that the ability of NF-κB binding to the MDR1 promoter was enhanced by paclitaxel treatment. By contrast, the PCR product was markedly decreased in the paclitaxel 0.006/TET cells, which indicated that TET attenuated the ability of NF-κB binding to the MDR1 promoter. On the whole, these data strongly
Figure 4. Tetrandrine (TET) prevents the paclitaxel-induced decrease in intracellular Rh123 accumulation. Intracellular Rh123 retention in U-2OS/control, U-2OS/TET, paclitaxel_{0.2} and paclitaxel_{0.006}/TET cell sublines were analyzed by flow cytometry. (A) U-2OS/control cells, (B) paclitaxel_{0.2} cells, (C) paclitaxel_{0.006}/TET cells, (D) U-2OS/TET cells. (E) Relative Rh123 accumulation was analyzed. Data are presented as the means ± SD. *P<0.05 vs. U-2OS/control group, #P<0.05 vs. paclitaxel_{0.2} group.

Figure 5. Tetrandrine (TET) inhibits the overexpression of P-glycoprotein (Pgp) by inhibiting NF-κB signaling. (A and B) Luciferase activity of multidrug resistance gene 1 (MDR1) and NF-κB reporter genes were measured using a dual-luciferase reporter assay. (C) The expression levels of NF-κB and p-IκB-α were determined by western blot analysis. (D and E) Relative NF-κB and p-IκB-α expression from (C) were analyzed. (F) NF-κB DNA-binding activity was determined by electrophoretic mobility shift assay (EMSA). (G) NF-κB binding ability to MDR1 promoter was determined by chromatin immunoprecipitation (ChIP). Data are presented as the means ± SD. *P<0.05 vs. U-2OS/control group, #P<0.05 vs. paclitaxel_{0.2} group.
indicated that TET inhibited the overexpression of Pgp by inhibiting NF-κB signaling.

Discussion

Overexpression of Pgp exhibits an important function on the development of MDR (11,12,23) and correlates well with an overall poor chemotherapy response and prognosis (43). Pgp acts as an energy-dependent membrane transporter, rapidly pumping out functionally and structurally unrelated chemotherapeutic drugs from cells. Inhibiting the initiation of MDR at the onset of chemotherapy may fundamentally assist in overcoming drug resistance. TET is an alkaloid isolated from the tuberous root of Stephania tetrandra. A previous study revealed that TET significantly reversed MDR in different cancer cell lines by promoting Pgp ATPase activity and suppressing Pgp function (44). Moreover, TET has been shown to prevent the leukemia cell line, K562, from developing MDR through the prevention of MDR1 transcription (37). In the present study, we established an MDR osteosarcoma cell model and demonstrated that the initiation of MDR was prevented by TET by suppressing Pgp overexpression in human osteosarcoma cells.

To establish an MDR cell line in vitro, the cells were treated with stepwise increased concentrations of paclitaxel in culture medium, which was considered the classic in vitro serial selection approach (21,23,38). We successfully established the osteosarcoma MDR cell line from the drug sensitive cell line, U-2OS, using a similar procedure. The results revealed that the cells treated with paclitaxel alone acquired MDR with resistance to paclitaxel and other Pgp substrates, such as doxorubicin, docetaxel and vincristine. However, the cells treated with the paclitaxel-TET combination remained sensitive to chemotherapeutic drugs. Furthermore, the cells treated with paclitaxel alone or with the paclitaxel-TET combination did not develop drug resistance to the non-Pgp substrates cisplatin and methotrexate. These results suggest that TET may inhibit the development of MDR in osteosarcoma by inhibiting Pgp overexpression.

It has been reported that MDR can be mediated by Pgp in osteosarcoma (45). We observed that the long-term treatment of osteosarcoma cells with paclitaxel induced Pgp overexpression. The overexpression of Pgp leads to the decreased intracellular accumulation of chemotherapeutic agents, thus preventing the drugs from exerting their cytotoxic effects (11,12,46). Our data demonstrated that the cells treated with paclitaxel alone exhibited reduced drug intracellular accumulation of the Pgp substrate, Rh123. In comparison, the cells treated with the paclitaxel-TET combination displayed no obvious difference with the sensitive control cells, indicating that TET allowed the retention of chemotherapeutic drugs during paclitaxel treatment. Consequently, TET enabled the osteosarcoma cells to maintain sensitivity to chemotherapeutic drugs and inhibited the introduction of MDR by preventing Pgp overexpression.

NF-κB is an important transcription factor in carcinoma. NF-κB is usually located in the cytoplasm of quiescent cells. In response to stimuli, NF-κB isolates from its inhibitory partner IκB, then translocates to the nucleus to regulate downstream genes transcription by binding to κB-binding sites. It has been reported that TET can inhibit NF-κB activation in various cells, such as pancreatic cells, peripheral blood T cells and brain cells (47,48). A previous study revealed that the decreased NF-κB expression resulted in the downregulation of MDR1 and Pgp, which suggested that NF-κB is involved in MDR regulation (49). Our results demonstrated that the cells cultured with paclitaxel alone exhibited significantly elevated promoter activities of MDR1 and NF-κB, which were significantly inhibited following paclitaxel-TET combination treatment, suggesting that TET inhibited the promoter activity of MDR1, possibly by downregulating NF-κB activity, at least in part. Subsequently, we demonstrated that the expression levels of p-IκB-α and nuclear NF-κB were both decreased in the cells cultured with the paclitaxel-TET combination. Moreover, the NF-κB DNA-binding activity and the ability of NF-κB to bind to the MDR1 promoter were attenuated as compared with the cells cultured with paclitaxel alone, which suggested that TET inhibited NF-κB activation and subsequently regulated MDR1 gene expression. Collectively, TET inhibited the overexpression of Pgp by inhibiting NF-κB signaling.

In conclusion, our findings indicated that TET prevented the introduction of paclitaxel-induced MDR in osteosarcoma cells by inhibiting Pgp overexpression through a mechanism involving the inhibition of NF-κB signaling. Given its preventive effect on MDR, TET holds promise to extend the long-term efficacy of chemotherapy in patients with osteosarcoma.

Acknowledgements

The authors would sincerely like to thank the members of the Department of Orthopaedic Traumatology, Tianjin Hospital and the Department of Orthopaedics, Jixian People's Hospital for their valuable input/suggestions concerning the present manuscript.

References

TETRANDRINE PREVENTS MULTIDRUG RESISTANCE IN U-2OS OSTEOSARCOMA CELLS


